Experience the Quality With Free AOCNP Exam Questions That Helps Candidates Pass

Postoperative colonoscopic surveillance aims to detect metachronous neoplasia and anastomotic recurrence. If a high-quality colonoscopy was completed before surgery, the first surveillance colonoscopy is recommended at 1 year after resection. If the preoperative exam was incomplete because of obstruction or poor prep, perform colonoscopy within 3–6 months post-op to clear the colon. When the 1-year exam is normal, the next interval is generally at 3 years, then every 5 years, adjusting for findings (e.g., adenomas requiring shorter intervals) and patient factors. Routine 6-month colonoscopy (Option A) is unnecessary when baseline is complete. Stopping surveillance (Option C) overlooks ongoing risk. Annual colonoscopy indefinitely (Option D) increases burden without benefit in average-risk postoperative patients with negative exams. The APRN should ensure recall systems are set, review pathology to tailor intervals, counsel on lifestyle risk reduction (tobacco cessation, diet, physical activity), and coordinate CEA imaging/lab surveillance as indicated by stage and guidelines.

The benefit of prostate cancer screening accrues slowly and is unlikely to outweigh harms (false positives, biopsies, overdiagnosis, treatment toxicity) when life expectancy is <10 years or significant comorbidity limits curative treatment. For older adults with multimorbidity and no symptoms, discontinuing PSA screening is appropriate. Discuss why—competing mortality risks, slow natural history of many screen-detected cancers—and emphasize prompt evaluation for new symptoms (bone pain, obstructive/hematuria) rather than routine PSA testing. MRI screening (Option C) is not recommended for average-risk asymptomatic men. Extending the interval (Option D) still exposes to low-value testing. Continuing annually (Option A) may lead to cascades of testing without meaningful survival benefit. APRNs should incorporate shared decision-making, deprescribe low-value services, and pivot to interventions with clear benefit: vaccination, tobacco cessation support, fall prevention, BP/lipid/diabetes control, and advance care planning. Document the rationale and communicate with primary care to ensure consistent messaging and avoid fragmented, duplicative testing.

Time to antibiotics is critical in febrile neutropenia, and nurse-initiated protocols can reduce delays. Safe, compliant implementation requires formal, approved standing orders with well-defined triggers (e.g., temp ≥38.0°C in a chemotherapy patient), scope (cultures, lactate, IV fluids, antipseudomonal β-lactam), and explicit exclusion criteria (instability, allergy, indwelling line infections). Competency-based training, simulation, and annual validation ensure reliability. APRN/physician oversight, real-time availability, and audit/feedback (door-to-antibiotic time, cultures-before-antibiotics) maintain quality. Ad hoc actions (Option A) risk variability and liability; automatic antibiotic release (Option C) without assessment is unsafe. Restricting all steps to APRNs (Option D) may prolong delays and ignores team-based care models. The APRN co-leads policy design, metrics, and continuous improvement.

Evidence supports regular physical activity during and after cancer treatment to reduce fatigue, improve cardiorespiratory fitness, preserve bone mass, and enhance quality of life. A practical target is ≥150 minutes/week of moderate-intensity aerobic exercise (e.g., brisk walking, cycling) or 75 minutes of vigorous activity, plus strength training involving major muscle groups 2–3 days/week. Begin at tolerated levels and progress gradually; incorporate flexibility and balance. Supervised programs are useful for deconditioning or comorbidities. Resistance training is SAFE for individuals with or at risk for lymphedema when progressed sensibly and paired with compression as advised—contrary to Option A. Bed rest (Option C) worsens fatigue and deconditioning. HIIT-only plans (Option D) are not appropriate for all and may be unrealistic early on. The APRN should screen for contraindications (uncontrolled cardiopulmonary disease, severe anemia), provide referrals to oncology rehab/exercise physiologists, counsel on hydration and foot care (for neuropathy), and document goals in the survivorship care plan with follow-up on adherence and barriers.

Phase I trials establish foundational safety data for new agents or combinations. The principal aims are to characterize pharmacokinetics/pharmacodynamics, identify dose-limiting toxicities (DLTs), and determine the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) and schedule. While signals of antitumor activity may be observed, efficacy is not the primary endpoint. Phase II then explores activity in defined populations, and phase III tests comparative effectiveness against standard therapies. The APRN’s role includes meticulous adverse event assessment and grading (e.g., CTCAE), timely reporting, protocol-directed management of toxicities, patient education on risks/benefits, and rigorous consent processes that communicate uncertainties inherent to early-phase research. Understanding eligibility criteria, washout periods, and concomitant medication restrictions prevents protocol deviations. Close collaboration with research coordinators, pharmacists, and investigators ensures data integrity and participant safety, supporting ethical conduct and scientific validity of trial outcomes.